Xolair gets black box labeling

Share this article:

The FDA has announced new "black box" labeling for Genentech's Xolair (omalizumab) to address the risk of anaphylaxis in patients using the asthma drug.

The new labeling, the FDA’s strictest, indicates that patient reports following the drug's approval in 2003 through 2006 noted cases of anaphylaxis were seen in roughly two out of 1000 patients.

Genentech collaborates with Novartis on the marketing of Xolair, which had $425 million in global sales last year.


 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions